# Lower-Risk Myelodysplastic Syndromes
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
About Storm Media
The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.
About Storm Media
The Storm Media (world.storm.mg) is dedicated to bringing Taiwan's voice to the world. We deliver timely, balanced, and internationally oriented reporting and in-depth analysis on key issues including democratic politics, cross-strait relations, geopolitics, Indo-Pacific strategy, technology industry, and economic trends — helping global readers gain a deeper understanding of Taiwan and the Asia-Pacific region.
Copyright © 2026, Storm Media Group. All rights reserved.
Version: 20261022-081558